½ÃÀ庸°í¼­
»óǰÄÚµå
1523169

Á¤¹ÐÀÇ·á ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2030³â)

Precision Medicine Market Report: Trends, Forecast and Competitive Analysis to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Lucintel | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Á¤¹ÐÀÇ·á µ¿Çâ°ú Àü¸Á

¼¼°è Á¤¹ÐÀÇÇÐ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö 9.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2030³â±îÁö ¾à 1,436¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í µ¿¹Ý Áø´Ü ¹× À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ÀÔ´Ï´Ù. ¼¼°è Á¤¹ÐÀÇÇÐ ½ÃÀåÀÇ ¹Ì·¡´Â Á¾¾ç, Èñ±ÍÁúȯ, °¨¿°¼º Áúȯ, Ç÷¾×Áúȯ ½ÃÀå¿¡¼­ ±âȸ°¡ ÀÖÀ¸¸ç À¯¸ÁÇÑ ½ÃÀåÀ¸·Î Æò°¡¹Þ°í ÀÖ½À´Ï´Ù.

ºÎ¹®º° Á¤¹ÐÀÇÇÐ

ÀÌ º¸°í¼­´Â ¼¼°è Á¤¹ÐÀÇ·áÀÇ À¯Çüº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ¿¹ÃøÀ» ´ã°í ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á ½ÃÀå ÀλçÀÌÆ®

LucintelÀº ¿¹Ãø ±â°£ µ¿¾È ¾ïÁ¦Á¦°¡ °¡Àå Å« ºÎ¹®À¸·Î ³²À» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀå¿¡¼­ Á¾¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ºÎ¹®À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÚÁÖ ¹¯´Â Áú¹®

Q1. ½ÃÀå ±Ô¸ð :

A1. ¼¼°è Á¤¹ÐÀÇ·á ½ÃÀåÀº 2030³â±îÁö ¾à 1,436¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q2. ½ÃÀå ¼ºÀå ¿¹ÃøÀº ´ÙÀ½°ú °°½À´Ï´Ù.

A2. ¼¼°è Á¤¹ÐÀÇÇÐ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 9.5%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q3. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ´ÙÀ½°ú °°½À´Ï´Ù.

A3. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í µ¿¹Ý Áø´Ü ¹× À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ÀÔ´Ï´Ù.

Q4. ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

A4. Á¤¹ÐÀÇÇÐ ½ÃÀåÀÇ ¹Ì·¡´Â Á¾¾ç, Èñ±ÍÁúȯ, °¨¿°Áúȯ, Ç÷¾×Áúȯ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ±âȸ°¡ ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q5. ½ÃÀå ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

A5.Á¤¹ÐÀÇ·á ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

  • Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Bristol Myers Squibb
  • AstraZeneca
  • Gilead Sciences
  • AbbVie
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Sanofi

Q6. ÇâÈÄ °¡Àå Å« ½ÃÀå ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

A6. LucintelÀº ¿¹Ãø ±â°£ µ¿¾È ¾ïÁ¦Á¦°¡ °¡Àå Å« ºÎ¹®À¸·Î ³²À» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

Q7. ½ÃÀå¿¡¼­ ÇâÈÄ 5³â°£ °¡Àå Å« ½ÃÀåÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ªÀº ¾îµðÀԴϱî?

A7. ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q8. º¸°í¼­ »ç¿ëÀÚ Á¤Àǰ¡ °¡´ÉÇմϱî?

A8. ³×. LucintelÀº Ãß°¡ ºñ¿ë¾øÀÌ 10%ÀÇ »ç¿ëÀÚ Á¤ÀǸ¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå : ½ÃÀå ¿ªÇÐ

  • ¼­·Ð, ¹è°æ, ºÐ·ù
  • °ø±Þ¸Á
  • ¾÷°è ÃËÁø¿äÀΰú °úÁ¦

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2030³â)

  • °Å½Ã°æÁ¦ µ¿Çâ(2018-2023³â)°ú ¿¹Ãø(2024-2030³â)
  • ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå µ¿Çâ(2018-2023³â)°ú ¿¹Ãø(2024-2030³â)
  • À¯Çüº° ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
    • ¾ïÁ¦Á¦
    • ´ÜŬ·ÐÇ×ü
    • ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á
    • Ç×¹ÙÀÌ·¯½ºÁ¦ ¹× Ç×·¹Æ®·Î¹ÙÀÌ·¯½ºÁ¦
    • ±âŸ
  • ÀûÀÀÁõº° ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
    • Á¾¾ç
    • Èñ±ÍÁúȯ
    • °¨¿°Áõ
    • Ç÷¾×Áúȯ
    • ±âŸ
  • ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
    • º´¿ø ¹× Ŭ¸®´Ð
    • ÀçÅÃÄ¡·á

Á¦4Àå Áö¿ªº° ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2023³â)

  • Áö¿ªº° ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
  • ºÏ¹ÌÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
  • À¯·´ÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
  • ±âŸ Áö¿ªÀÇ Á¤¹ÐÀÇ·á ½ÃÀå

Á¦5Àå °æÀï ºÐ¼®

  • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
  • ¿î¿µ ÅëÇÕ
  • PorterÀÇ Five Forces ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ¿Í Àü·« ºÐ¼®

  • ¼ºÀå ±âȸ ºÐ¼®
  • ¼¼°è Á¤¹ÐÀÇ·á ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ
  • Àü·« ºÐ¼®
    • ½ÅÁ¦Ç° °³¹ß
    • ¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå ´É·Â È®´ë
    • ¼¼°è Á¤¹ÐÀÇ·á ½ÃÀå¿¡¼­ÀÇ ÀμöÇÕº´(M&A) ¹× ÇÕÀÛÅõÀÚ(JV)
    • ÀÎÁõ°ú ¶óÀ̼±½Ì

Á¦7Àå ÁÖ¿ä ±â¾÷ °³¿ä

  • Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Bristol Myers Squibb
  • AstraZeneca
  • Gilead Sciences
  • AbbVie
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Sanofi
LSH 24.09.09

Precision Medicine Trends and Forecast

The future of the global precision medicine market looks promising with opportunities in the oncology, rare disease, infectious disease, and hematological disorder markets. The global precision medicine market is expected to reach an estimated $143.6 billion by 2030 with a CAGR of 9.5% from 2024 to 2030. The major drivers for this market are increasing demand for personalized treatment and rising preference for companion diagnostics & genetic testing.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Precision Medicine by Segment

The study includes a forecast for the global precision medicine by type, indication, end use, and region.

Precision Medicine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Inhibitor Drugs
  • Monoclonal Antibodies
  • Cell & Gene Therapy
  • Antiviral & Anti-Retroviral Drugs
  • Others

Precision Medicine Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Rare Diseases
  • Infectious Diseases
  • Hematological Disorders
  • Others

Precision Medicine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Home Care Settings

Precision Medicine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Precision Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies precision medicine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the precision medicine companies profiled in this report include-

  • Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Bristol Myers Squibb
  • AstraZeneca
  • Gilead Sciences
  • AbbVie
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Sanofi

Precision Medicine Market Insights

Lucintel forecasts that inhibitor drug will remain the largest segment over the forecast period.

Within this market, oncology will remain the largest segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Precision Medicine Market

Market Size Estimates: Precision medicine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Precision medicine market size by type, indication, end use, and region in terms of value ($B).

Regional Analysis: Precision medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, indications, end uses, and regions for the precision medicine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the precision medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the precision medicine market size?

Answer: The global precision medicine market is expected to reach an estimated $143.6 billion by 2030.

Q2. What is the growth forecast for precision medicine market?

Answer: The global precision medicine market is expected to grow with a CAGR of 9.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the precision medicine market?

Answer: The major drivers for this market are increasing demand for personalized treatment and rising preference for companion diagnostics & genetic testing.

Q4. What are the major segments for precision medicine market?

Answer: The future of the precision medicine market looks promising with opportunities in the oncology, rare disease, infectious disease, and hematological disorder markets.

Q5. Who are the key precision medicine market companies?

Answer: Some of the key precision medicine companies are as follows:

  • Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Bristol Myers Squibb
  • AstraZeneca
  • Gilead Sciences
  • AbbVie
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Sanofi

Q6. Which precision medicine market segment will be the largest in future?

Answer: Lucintel forecasts that inhibitor drug will remain the largest segment over the forecast period.

Q7. In precision medicine market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the precision medicine market by type (inhibitor drugs, monoclonal antibodies, cell & gene therapy, antiviral & anti-retroviral drugs, and others), indication (oncology, rare diseases, infectious diseases, hematological disorders, and others), end use (hospitals & clinics and home care settings), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Precision Medicine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Precision Medicine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Precision Medicine Market by Type
    • 3.3.1: Inhibitor Drugs
    • 3.3.2: Monoclonal Antibodies
    • 3.3.3: Cell & Gene Therapy
    • 3.3.4: Antiviral & Anti-Retroviral Drugs
    • 3.3.5: Others
  • 3.4: Global Precision Medicine Market by Indication
    • 3.4.1: Oncology
    • 3.4.2: Rare Diseases
    • 3.4.3: Infectious Diseases
    • 3.4.4: Hematological Disorders
    • 3.4.5: Others
  • 3.5: Global Precision Medicine Market by End Use
    • 3.5.1: Hospitals & Clinics
    • 3.5.2: Home Care Settings

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Precision Medicine Market by Region
  • 4.2: North American Precision Medicine Market
    • 4.2.1: North American Precision Medicine Market by Type: Inhibitor Drugs, Monoclonal Antibodies, Cell & Gene Therapy, Antiviral & Anti-Retroviral Drugs, and Others
    • 4.2.2: North American Precision Medicine Market by Indication: Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, and Others
  • 4.3: European Precision Medicine Market
    • 4.3.1: European Precision Medicine Market by Type: Inhibitor Drugs, Monoclonal Antibodies, Cell & Gene Therapy, Antiviral & Anti-Retroviral Drugs, and Others
    • 4.3.2: European Precision Medicine Market by Indication: Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, and Others
  • 4.4: APAC Precision Medicine Market
    • 4.4.1: APAC Precision Medicine Market by Type: Inhibitor Drugs, Monoclonal Antibodies, Cell & Gene Therapy, Antiviral & Anti-Retroviral Drugs, and Others
    • 4.4.2: APAC Precision Medicine Market by Indication: Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, and Others
  • 4.5: ROW Precision Medicine Market
    • 4.5.1: ROW Precision Medicine Market by Type: Inhibitor Drugs, Monoclonal Antibodies, Cell & Gene Therapy, Antiviral & Anti-Retroviral Drugs, and Others
    • 4.5.2: ROW Precision Medicine Market by Indication: Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Precision Medicine Market by Type
    • 6.1.2: Growth Opportunities for the Global Precision Medicine Market by Indication
    • 6.1.3: Growth Opportunities for the Global Precision Medicine Market by End Use
    • 6.1.4: Growth Opportunities for the Global Precision Medicine Market by Region
  • 6.2: Emerging Trends in the Global Precision Medicine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Precision Medicine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Precision Medicine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Hoffmann-La Roche
  • 7.2: Novartis
  • 7.3: Pfizer
  • 7.4: Bristol Myers Squibb
  • 7.5: AstraZeneca
  • 7.6: Gilead Sciences
  • 7.7: AbbVie
  • 7.8: Eli Lilly and Company
  • 7.9: GlaxoSmithKline
  • 7.10: Sanofi
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦